Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma Real World Evidence from the French Early Access Program - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Blood Année : 2018

Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma Real World Evidence from the French Early Access Program

Krimo Bouabdallah
  • Fonction : Auteur
Remy Dulery
Laurent Dercle

Domaines

Cancer

Dates et versions

hal-02076926 , version 1 (22-03-2019)

Identifiants

Citer

Roch Houot, Guillaume Manson, Jean-Baptiste Mear, Charles Herbaux, Jean Marc Schiano de Collela, et al.. Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma Real World Evidence from the French Early Access Program. Blood, 2018, 132 (1), pp.1638. ⟨10.1182/blood-2018-99-110960⟩. ⟨hal-02076926⟩
108 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More